<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

Targeting Microbiomes & Biomarkers: Inflammation World Congress

Posted by MD Biosciences on Aug 20, 2015 4:30:00 PM


The 12th World Congress on Inflammation wrapped up on Wednesday August 12th after four days packed with cutting edge inflammatory research by key opinions leaders in the field. Presentations hit every aspect of the scientific spectrum from development of pre-clinical models through retrospective studies on new target therapies and everything in between. Highlights of the conference included the Keynote Lecture by Luke O’Neill of Trinity College Dublin, the Symposium “Mechanisms Underlying Microbiome-Mediated Inflammation”, and multiple discussions on identifying and targeting novel biomarkers of inflammatory diseases.

Read More

Topics: Inflammation, metabolic, Preclinical Discovery, Microbiome, Biomarkers, World Congress on Inflammation

Drug Discovery Success Rates | Role of Preclinical Study Design.

Posted by MD Biosciences on Apr 22, 2015 1:16:55 AM

In 2014, an article was published in Nature analyzing the clinical development success rates for investigational drugs. It's no surprise that the success rates are still somewhat dismal with 1 in 10 drugs that enter clinical phases pushing through to FDA approval. The article breaks down the success rate in each phase for differing classes of drugs as well as various therapeutic indications. NMEs were found to have the lowest success rates in every phase of development (7.5%) whereas biologics had nearly two times the success rate (14.6%).

Read More

Topics: Preclinical Discovery